vWF/ADAMTS13在慢性肾脏病中的临床意义  

Clinical significance of vWF/ADAMTS13 in chronic kidney disease

作　　者：沈蕾[1] 卢国元[1] 蒋丽琼[1] 马珍妮[2] 汪安友[2] 董宁征[2] 阮长耿[2] 

机构地区：[1]苏州大学附属第一医院肾脏病科,215006 [2]江苏省血液研究所卫生部血栓与止血重点实验室

出　　处：《江苏医药》2011年第13期1535-1537,共3页Jiangsu Medical Journal

基　　金：国家自然基金(30670904);2009年苏州大学医学部研究生创新基金

摘　　要：目的探讨血管性血友病因子(vWF)及其裂解蛋白酶(ADAMTS13)在慢性肾脏病中的临床意义。方法选取慢性肾脏病患者47例为实验组(A组),其中原发性肾小球疾病(A1组)24例,狼疮性肾炎(A2组)23例;另设体检健康成人30例为正常对照组(B组)。A1组患者均行肾活检,其中非膜性肾病15例(C1组),膜性肾病9例(C2组)。ELISA法、FRETS-vWF73法分别检测血浆中vWF含量、ADAMTS13活性,免疫组化法检测vWF和ADAMTS13在肾脏的表达。结果与B组相比,A1、A2组血浆中ADAMTS13活性降低,而vWF浓度升高(P<0.01);A组患者血浆vWF/ADAMTS13与24-h尿蛋白定量呈正相关(r=0.477,P<0.01);C2组ADAMTS13的表达明显低于C1组(P<0.05)。结论血浆中vWF与ADAMTS13的平衡失调可能与慢性肾脏病的临床和病理类型有关。Objective To investigate the clinical significance of von Willebrand factor（vWF） and its schizolysis protease（ADAMTS13） in chronic kidney diseases.Methods Forty-seven patients with chronic kidney diseases were collected as experimental group（group A）,which was further divided into 2 groups of A1（with primary glomerular diseases,24 cases） and A2（with lupus nephritis,23 cases）.And 30 healthy people were taken as the normal control group（group B）.The renal biopsy was performed in the patients of group A1,which included non-membranous nephropathy（group C1,15 cases） and membranous nephropathy（group C2,9 cases）.Plasma content of vWF and the activity of ADAMTS13 were detected by ELISA and FRETS-vWF73 assay,respectively.The expressions of vWF and ADAMTS13 in the kidney were detected by immunohistochemisty.Results Compared with group B,the activities of ADAMTS13 were decreased,but the levels of vWF were increased in groups of A1 and A2（P0.01）.The vWF/ADAMTS13 was positively correlated with 24-h urine protein in group A（r=0.477,P0.01）.The expression of ADAMTS13 in group C2 was significantly lower than that in group C1（P0.05）.Conclusion The imbalance of vWF and ADAMTS13 may be related to the clinical and pathological type of chronic kidney diseases.

关 键 词：血管性血友病因子 血管性血友病因子裂解蛋白酶 慢性肾脏病 

分 类 号：R692[医药卫生—泌尿科学]